With two new spaces having opened up in our rundown of the top 10 generics and biosimilars companies this year – allowing Dr Reddy’s and Cipla to ascend out of the middle table covering positions 11-30 in our ranking, and into the top 10 (see sidebar) – this has left room for further firms to climb up the charts in the second part of the Generics Bulletin Top 50.
The Generics Bulletin Top 50, Part Two: Mid-Table Firms Move Up And Down
As Certain Companies Ascend, Others Are Moving In The Opposite Direction
In the second part of Generics Bulletin’s Top 50, we look at the mid-table players and how they have shifted positions this year.
More from Company Rankings
• By
This article compiles all of the data from Generics Bulletin’s 2024 ranking of the Top 50 firms across the generics and biosimilars industry, including additional details of how the various financial figures stack up.
• By
In the third instalment of this year’s Generics Bulletin Top 50, we look at some of the firms that have been eliminated from the bottom of our table as others have entered the picture.
• By
In the second part of Generics Bulletin’s Top 50, we see some companies rising up the rankings of generics and biosimilars players worldwide, passing others that are moving in the opposite direction.
• By
A deceptively familiar top 10 of generics and biosimilars industry leaders this year belies the significant evolutions seen for major off-patent players over the past 12 months. We reveal the changes under the surface in the first instalment of this year’s Generics Bulletin Top 50.
More from Market Intelligence
• By
Dementia treatment memantine saw the steepest rise in its UK trade price in November, according to the latest figures from WaveData.
• By
After a few months of steep UK price rises for apixaban generics, October saw a correction as average prices headed in the opposite direction, the latest figures from WaveData reveal.
• By
Generics of the schizophrenia treatment Latuda generated more than $4bn in savings a year after their 2022 approval, according to an FDA study.